|
1) 2009年版 日本透析医学会｢腹膜透析ガイドライン｣. 透析会誌. 2009; 42: 285-315
|
|
|
|
|
2) Honda K, Hamada C, Nakayama M, et, al. Peritoneal Biopsy Study Group of the Japanese Society for Peritoneal Dialysis. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol. 2008; 3: 720-8
|
|
|
|
|
3) Sherif AM, Nakayama M, Maruyama Y, et al. Quantitative assessment of the peritoneal vessel density and vasculopathy in CAPD patients. Nephrol Dial Transplant. 2006; 21: 1675-81. Epub 2006 Mar 22
|
|
|
|
|
|
4) Linden T, Cohen A, Deppisch R, et al. 3, 4-Dideoxyglucosone-3-ene (3, 4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int. 2002; 62: 697-703
|
|
|
|
|
|
5) Welten AG, Schalkwijk CG, ter Wee PM, et al. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int. 2003; 23: 213-21
|
|
|
|
|
|
6) De Vriese AS, Tilton RG, Stephan CC, et al. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol. 2001; 12: 1734-41
|
|
|
|
|
|
7) Aroeira LS, Aguilera A, Sánchez-Tomero JA, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol. 2007; 18: 2004-13
|
|
|
|
|
|
8) Yokoyama K, Yoshida H, Matsuo N, et al. Serum beta2 microglobulin (beta2MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients. Clin Nephrol. 2008; 69: 121-6
|
|
|
|
|
|
9) Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008; 118: 1748-57
|
|
|
|
|
|
10) Hirahara I, Kusano E, Yanagiba S, et al. Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit Dial Int. 2006; 26: 380-92
|
|
|
|
|
|
11) Hirahara I, Ishibashi Y, Kaname S, et al. Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant. 2009; 24: 437-47. Epub 2008 Sep 12
|
|
|
|
|
|
12) Chin AI, Yeun JY. Encapsulating peritoneal sclerosis: an unpredictable and devastating complication of peritoneal dialysis. Am J Kidney Dis. 2006; 47: 697-712. Review. No abstract available
|
|
|
|
|
|
13) Augustine T, Brown PW, Davies SD, et al. Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract. 2009; 111: c149-54; discussion c154. Epub 2009 Jan 16
|
|
|
|
|
|
14) Schmidt DW, Flessner MF. Pathogenesis and treatment of encapsulating peritoneal sclerosis: basic and translational research. Perit Dial Int. 2008; 28 Suppl 5: S10-5. Review. Erratum in: Perit Dial Int. 2009; 29: 131-2
|
|
|
|
|
|
15) Brown MC, Simpson K, Kerssens JJ, et al. Scottish Renal Registry. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol. 2009; 4: 1222-9. Epub 2009 Jun 18
|
|
|
|
|
|
16) Korte MR, Yo M, Betjes MG, et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant. 2007; 22: 2412-4. Epub 2007 Mar 29. No abstract available
|
|
|
|
|
|
17) Yamamoto R, Otsuka Y, Nakayama M, et al. Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin Exp Nephrol. 2005; 9: 148-52
|
|
|
|
|
18) Otsuka Y, Nakayama M, Ikeda M, et al. Restoration of peritoneal integrity after withdrawal of peritoneal dialysis: characteristic features of the patients at risk of encapsulating peritoneal sclerosis. Clin Exp Nephrol. 2005; 9: 315-9
|
|
|
|
|
|
19) 山本忠司, 出雲谷剛, 奥野仙二, 他. 腹膜透析中止後腹腔洗浄中の被嚢性腹膜硬化症予防についてのコホート研究. 透析会誌. 2007; 40: 491-500
|
|
|
|
|
|
20) Hirahara I, Inoue M, Okuda K, et al. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis-a multicentre study in Japan. Nephrol Dial Transplant. 2007; 22: 560-7. Epub 2006 Oct 11
|
|
|
|
|
|
21) Sherif AM, Yoshida H, Maruyama Y, et al. Comparison between the pathology of encapsulating sclerosis and simple sclerosis of the peritoneal membrane in chronic peritoneal dialysis. Ther Apher Dial. 2008; 12: 33-41
|
|
|
|
|
|
22) 宮崎正信, 中山昌明, 川西秀樹, 他. Japan Fluid Study(JFS)からの報告－長期腹膜透析排液研究の結果(第2報)－. 腎と透析(腹膜透析2008). 2008; 65(別冊): 389-90
|
|
|
|
|
|
23) Summers AM, Brenchley PE. An international encapsulating peritoneal sclerosis registry and DNA bank: why we need one now. Perit Dial Int. 2006; 26: 559-63. Review. No abstract available
|
|
|
|
|
|
24) Nishina M, Endoh M, Suzuki D, et al. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Clin Exp Nephrol. 2004; 8: 339-43
|
|
|
|
|
|
25) Shimizu H, Ishibashi Y, Kumagai T, et al. Long-term effect of peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration on peritoneum: a case report. Perit Dial Int. 2007; 27: 92-4
|
|
|
|
|
|
26) Nakayama M, Miyazaki M, Honda K, et al. Research Group of NEXT-PD.: Status of PD withdrawal and the incidence of encapsulating peritoneal sclerosis(EPS) in the newly integrated PD strategy in Japan－neutral solution and extraneal for present PD outcome in Japan (NEXT-PD). J Am Soc Nephrol. 2009; 20: 720A
|
|
|
|
|